Gilead Sciences Inc. NASDAQ GILD and Galapagos NV Euronext & NASDAQ GLPG today announced that the Marketing Authorization Application MAA for filgotinib an investigational oral selective JAK1 inhibitor for the treatment of adults with rheumatoid ar...
↧